Tags : Neutropenia

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration

Vartika Singh November 27, 2018

Shots: The approval is based on non-inferiority data with the reference biologic (Neulasta) showing biosimilarity in terms of safety, efficacy and quality Ziextenzo is a long-lasting form of filgrastim indicated […]readmore

Biosimilars Regulatory

Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

Vartika Singh November 26, 2018

Shots: Pelmeg (Pegfilgrastim, Biosimilar) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic CT for malignancy CHMP recommends Pelmeg based […]readmore

Tags : Neutropenia

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration

Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Neutropenia

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration

Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company